Recent Finacing
Recent Raise
Dyne Therapeutics develops targeted oligonucleotide therapies for DMD, DM1, and FSHD using its FORCE antibody–oligonucleotide platform to enable muscle-specific delivery to skeletal, cardiac, and smooth muscle.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
